Compare Banco Santander SA (SAN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs TransMedics Group Inc — how do they compare? Banco Santander SA trades at $14.65 (market cap $214.37B), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: Banco Santander SA is far larger — about 71.5× TransMedics Group Inc's market cap, and Banco Santander SA pays a 1.9% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SAN | TMDX | |
|---|---|---|
Market Cap | $214.37B | $3.00B |
Sector | Financials | Technology |
52-Week High | $15.05 | $150.42 |
52-Week Low | $9.65 | $61.99 |
Dividend Yield | 1.9% | — |
Enterprise Value | — | $3.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 14.47 and a net income margin of 26.25%, with Q1 2026 earnings beating expectations but Q2 missing. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence and diversifying the banking franchise.
Outlook is positive with analyst consensus at 'Moderate Buy' (64% buy ratings), though risks include volatile cash flows and high debt levels. Revenue growth is steady, but negative operating cash flow in 2024-2025 warrants monitoring. The stock offers value with solid profitability, but investors should weigh acquisition integration risks against expansion benefits.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
